# Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

> **NCT02204475** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir/Elbasvir
- **DRUG:** Boceprevir
- **DRUG:** PegIntron
- **DRUG:** Ribavarin

## Key facts

- **NCT ID:** NCT02204475
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204475, "Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02204475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*